Matthew S. Zabriskie

Publications

• MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β-chain Cytokine Receptor Endocytosis
  Blood. Feb, 2022  |   Pubmed ID: 34780648
• SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA
  Blood Cancer Discovery. May, 2021  |   Pubmed ID: 34027418
• Rabbit Models of Intracranial Atherosclerotic Disease for Pathological Validation of Vessel Wall MRI
  The Neuroradiology Journal. Jun, 2021  |   Pubmed ID: 33325806
• Apolipoprotein E Knockout Rabbit Model of Intracranial Atherosclerotic Disease
  Animal Models and Experimental Medicine. Jun, 2020  |   Pubmed ID: 32613180
• Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Mutants
  Cancer Cell. Oct, 2019  |   Pubmed ID: 31543464
• A Novel Fusion in Pediatric T-cell Acute Lymphoblastic Leukemia
  Haematologica. Feb, 2018  |   Pubmed ID: 29284681
• Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
  Leukemia. Dec, 2017  |   Pubmed ID: 28819281
• A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2016  |   Pubmed ID: 26673800
• Limited Efficacy of BMS-911543 in a Murine Model of Janus Kinase 2 V617F Myeloproliferative Neoplasm
  Experimental Hematology. Jul, 2015  |   Pubmed ID: 25912019
• A Coiled-coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-mutant Chronic Myeloid Leukemia
  Leukemia. Aug, 2015  |   Pubmed ID: 25721898
• Radotinib is an Effective Inhibitor of Native and Kinase Domain-mutant BCR-ABL1
  Leukemia. Sep, 2015  |   Pubmed ID: 25676420
• ShRNA Library Screening Identifies Nucleocytoplasmic Transport As a Mediator of BCR-ABL1 Kinase-independent Resistance
  Blood. Mar, 2015  |   Pubmed ID: 25573989
• Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-resistant Chronic Myeloid Leukemia
  Leukemia. Mar, 2015  |   Pubmed ID: 25134459
• BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-positive Leukemia
  Cancer Cell. Sep, 2014  |   Pubmed ID: 25132497
• Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis
  Cancer Research. Jun, 2013  |   Pubmed ID: 23576564
• Composé Mutations BCR-ABL1 Kinase De Tyrosine Inhibiteur Résistant CML : Fréquence Et Relations Clonales
  Blood. Jan, 2013  |   Pubmed ID: 23223358
• Pushing the Limits of Targeted Therapy in Chronic Myeloid Leukaemia
  Nature Reviews. Cancer. Jul, 2012  |   Pubmed ID: 22825216
• Nilotinib and MEK Inhibitors Induce Synthetic Lethality Through Paradoxical Activation of RAF in Drug-resistant Chronic Myeloid Leukemia
  Cancer Cell. Dec, 2011  |   Pubmed ID: 22169110
• The BCR-ABL35INS Insertion/truncation Mutant is Kinase-inactive and Does Not Contribute to Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
  Blood. Nov, 2011  |   Pubmed ID: 21908430